Ehud Segal
Overview
Explore the profile of Ehud Segal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
1108
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Braun M, Ashkenazi A, Beveridge R, Castanedo G, Wallweber H, Beresini M, et al.
J Med Chem
. 2024 May;
67(11):8708-8729.
PMID: 38748820
The lack of selective and safe in vivo IRE1α tool molecules has limited the evaluation of IRE1α as a viable target to treat multiple myeloma. Focus on improving the physicochemical...
2.
Zeng M, Grandner J, Bryan M, Verma V, Larouche-Gauthier R, Leclerc J, et al.
ACS Med Chem Lett
. 2023 Sep;
14(9):1179-1187.
PMID: 37736184
Cyclin-dependent kinases (CDKs) are key regulators of the cell cycle and are frequently altered in cancer cells, thereby leading to uncontrolled proliferation. In this context, CDK2 has emerged as an...
3.
Venkatanarayan A, Liang J, Yen I, Shanahan F, Haley B, Phu L, et al.
Cell Rep
. 2022 Feb;
38(6):110351.
PMID: 35139374
KRAS, which is mutated in ∼30% of all cancers, activates the RAF-MEK-ERK signaling cascade. CRAF is required for growth of KRAS mutant lung tumors, but the requirement for CRAF kinase...
4.
Yen I, Shanahan F, Lee J, Hong Y, Shin S, Moore A, et al.
Nature
. 2021 May;
594(7863):418-423.
PMID: 33953400
Although RAF monomer inhibitors (type I.5, BRAF(V600)) are clinically approved for the treatment of BRAF-mutant melanoma, they are ineffective in non-BRAF mutant cells. Belvarafenib is a potent and selective RAF...
5.
Harnoss J, Le Thomas A, Reichelt M, Guttman O, Wu T, Marsters S, et al.
Cancer Res
. 2020 Apr;
80(11):2368-2379.
PMID: 32265225
Cancer cells exploit the unfolded protein response (UPR) to mitigate endoplasmic reticulum (ER) stress caused by cellular oncogene activation and a hostile tumor microenvironment (TME). The key UPR sensor IRE1α...
6.
Harnoss J, Le Thomas A, Shemorry A, Marsters S, Lawrence D, Lu M, et al.
Proc Natl Acad Sci U S A
. 2019 Aug;
116(33):16420-16429.
PMID: 31371506
Multiple myeloma (MM) arises from malignant immunoglobulin (Ig)-secreting plasma cells and remains an incurable, often lethal disease despite therapeutic advances. The unfolded-protein response sensor IRE1α supports protein secretion by deploying...
7.
Jin L, Garcia J, Chan E, de la Cruz C, Segal E, Merchant M, et al.
Cancer Res
. 2017 Aug;
77(20):5564-5575.
PMID: 28819026
Resistance invariably develops to antiandrogen therapies used to treat newly diagnosed prostate cancers, but effective treatments for castration-resistant disease remain elusive. Here, we report that the transcriptional coactivator CBP/p300 is...
8.
Sensarn S, Zavaleta C, Segal E, Rogalla S, Lee W, Gambhir S, et al.
Mol Imaging Biol
. 2016 May;
18(6):820-829.
PMID: 27154508
Purpose: Early and effective detection of cancers of the gastrointestinal tract will require novel molecular probes and advances in instrumentation that can reveal functional changes in dysplastic and malignant tissues....
9.
Tiram G, Segal E, Krivitsky A, Shreberk-Hassidim R, Ferber S, Ofek P, et al.
ACS Nano
. 2016 Jan;
10(2):2028-45.
PMID: 26815014
The presence of dormant, microscopic cancerous lesions poses a major obstacle for the treatment of metastatic and recurrent cancers. While it is well-established that microRNAs play a major role in...
10.
McCleland M, Mesh K, Lorenzana E, Chopra V, Segal E, Watanabe C, et al.
J Clin Invest
. 2016 Jan;
126(2):639-52.
PMID: 26752646
Colon tumors arise in a stepwise fashion from either discrete genetic perturbations or epigenetic dysregulation. To uncover the key epigenetic regulators that drive colon cancer growth, we used a CRISPR...